Korea, Rep.

Data includes aggregated resistance rates for isolates (includes intermediate resistance) from blood and cerebrospinal fluid (i.e., invasive) from inpatients of all ages. Because of differences in scope of collections and testing methods, caution should be exercised in comparing across countries. For more details see methodology.

Country boundaries/designations do not represent CDDEP opinion concerning the legal status of any country, territory, city, or area of its authorities, or concerning the delimitation of its frontiers or boundaries.
Antibiotic use data are shown in defined daily doses (DDD) per 1,000 individuals. View data as Standard UnitsHide Errorbars

Pathogens:

Acinetobacter baumannii

Enterobacter aerogenes/cloacae

Enterococcus faecalis

Enterococcus faecium

Escherichia coli

Klebsiella pneumoniae

Pseudomonas aeruginosa

Salmonella Paratyphi

Salmonella Typhi

Staphylococcus aureus

Streptococcus pneumoniae

Antibiotics

Amikacin

Aminoglycosides

Aminoglycosides (high-level)

Aminopenicillins

Amoxicillin-clavulanate

Ampicillin-sulbactam

Carbapenems

Ceftazidime

Cephalosporins (3rd gen)

Fluoroquinolones

Glycylcyclines

Linezolid

Macrolides

Oxacillin (MRSA)

Penicillins

Piperacillin-tazobactam

Polymyxins

Rifampicin

Tetracyclines

Trimethoprim-sulfamethoxazole

Vancomycin

Sources

To learn how this data was collected, see our methodology overview.
Boundaries and names shown and the designation used on these maps do not imply the expression of any opinion whatsoever on the part of CDDEP concerning the legal status of any country, territory, city or area of its authorities, or concerning the delimitation of its frontiers or boundaries.